{
    "clinical_study": {
        "@rank": "72338", 
        "arm_group": {
            "arm_group_label": "Omega-3 fatty acids", 
            "arm_group_type": "Experimental", 
            "description": "Participants will take 3.9g/day of Eicosapentaenoic acid and docosahexaenoic acid for 4 months"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine how omega-3 fatty acids influence muscle protein\n      metabolism and mitochondrial physiology in the context of human aging."
        }, 
        "brief_title": "Omega-3 Fatty Acids to Combat Sarcopenia", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Sarcopenia", 
        "condition_browse": {
            "mesh_term": "Sarcopenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-35 or 65-85 years\n\n        Exclusion Criteria:\n\n          1. Current use of omega-3 nutritional supplements\n\n          2. Fasting plasma glucose \u2265126 mg/dL\n\n          3. Active coronary artery disease\n\n          4. Participation in structured exercise (>3 times per week for 30 minutes or longer)\n\n          5. Smoking\n\n          6. Medications known to affect muscle metabolism (e.g., beta blockers, corticosteroids,\n             tricyclic-antidepressants, benzodiazepines, opiates, barbiturates, anticoagulants)\n\n          7. Renal failure (serum creatinine > 1.5mg/dl)\n\n          8. Chronic active liver disease (Bilirubin > 17mmol/L, AST>144IU/L, or ALT>165IU/L)\n\n          9. Anti-coagulant therapy (warfarin/heparin)\n\n         10. INR >3\n\n         11. Use of systemic glucocorticoids\n\n         12. Chronic use of NSAIDS or aspirin\n\n         13. Pregnancy or breastfeeding\n\n         14. Alcohol consumption greater than 2 glasses/day\n\n         15. Hypothyroidism\n\n         16. Fish or shellfish allergy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "24", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 18, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02103842", 
            "org_study_id": "14-000639"
        }, 
        "intervention": {
            "arm_group_label": "Omega-3 fatty acids", 
            "intervention_name": "Omega-3 fatty acids", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 1, 2014", 
        "location": {
            "contact": {
                "email": "LANZA.IAN@MAYO.EDU", 
                "last_name": "Ian R Lanza, PhD", 
                "phone": "507-255-8147"
            }, 
            "facility": {
                "address": {
                    "city": "Rochester", 
                    "country": "United States", 
                    "state": "Minnesota", 
                    "zip": "55905"
                }, 
                "name": "Mayo Clinic"
            }, 
            "investigator": {
                "last_name": "Ian R Lanza, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Omega-3 Fatty Acids to Combat Sarcopenia", 
        "overall_contact": {
            "email": "LANZA.IAN@Mayo.edu", 
            "last_name": "Ian R Lanza, PhD", 
            "phone": "507-255-8147"
        }, 
        "overall_official": {
            "affiliation": "Mayo Clinic", 
            "last_name": "Ian R Lanza, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Skeletal muscle protein synthesis will be measured from the rate of incorporation of infused amino acids measured by mass spectrometry.", 
                "measure": "Change in Muscle protein synthesis", 
                "safety_issue": "No", 
                "time_frame": "Baseline and following 4 months intervention"
            }, 
            {
                "description": "Mitochondrial function will be measured in isolated mitochondria by high-resolution respirometry.", 
                "measure": "Change in Muscle mitochondrial function", 
                "safety_issue": "No", 
                "time_frame": "Baseline and following 4 months intervention"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02103842"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Mayo Clinic", 
            "investigator_full_name": "Ian R. Lanza", 
            "investigator_title": "PI", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Mayo Clinic", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Mayo Clinic", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}